Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ARWR

Arrowhead Pharmaceuticals Inc.

May 03 • 04:00PM ET

24.44

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IJH VB IWM VXF VBK IWO IJK IBB SCHA

Index	RUT	P/E	-	EPS (ttm)	-2.77	Insider Own	4.95%	Shs Outstand	123.90M	Perf Week	10.49%
Market Cap	3.03B	Forward P/E	-	EPS next Y	-2.50	Insider Trans	-4.08%	Shs Float	117.77M	Perf Month	-6.40%
Income	-296.81M	PEG	-	EPS next Q	-0.47	Inst Own	64.71%	Short Float	7.53%	Perf Quarter	-23.53%
Sales	181.74M	P/S	16.66	EPS this Y	-37.39%	Inst Trans	-1.58%	Short Ratio	6.98	Perf Half Y	-5.23%
Book/sh	1.49	P/B	16.38	EPS next Y	5.40%	ROA	-39.11%	Short Interest	8.87M	Perf Year	-39.20%
Cash/sh	1.78	P/C	13.75	EPS next 5Y	7.33%	ROE	-110.45%	52W Range	20.67 - 42.48	Perf YTD	-20.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.19%	ROI	-54.04%	52W High	-42.47%	Beta	0.95
Dividend TTM	-	Quick Ratio	3.73	Sales past 5Y	205.96%	Gross Margin	92.26%	52W Low	18.24%	ATR (14)	1.24
Dividend Ex-Date	-	Current Ratio	3.73	EPS Y/Y TTM	-89.69%	Oper. Margin	-164.75%	RSI (14)	48.48	Volatility	5.05% 4.61%
Employees	525	Debt/Eq	2.45	Sales Y/Y TTM	-34.71%	Profit Margin	-163.32%	Recom	1.53	Target Price	53.66
Option/Short	Yes / Yes	LT Debt/Eq	2.42	EPS Q/Q	-217.40%	Payout	-	Rel Volume	0.00	Prev Close	24.44
Sales Surprise	-89.52%	EPS Surprise	-54.81%	Sales Q/Q	-94.32%	Earnings	May 09 AMC	Avg Volume	1.27M	Price	24.44
SMA20	2.83%	SMA50	-10.78%	SMA200	-14.97%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-23	Initiated	BofA Securities	Buy	$29
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75
Dec-16-20	Initiated	UBS	Buy	$95
Nov-19-20	Initiated	Citigroup	Buy	$90
May-13-20	Initiated	RBC Capital Mkts	Outperform	$62
May-08-20	Upgrade	Oppenheimer	Perform → Outperform	$58
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$55 → $60
Mar-24-20	Upgrade	SVB Leerink	Underperform → Mkt Perform	$29

Show Previous Ratings

May-03-24 07:26AM	Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug (MT Newswires)
May-02-24 04:01PM	Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma (Business Wire)
Apr-29-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences (Business Wire)
Apr-26-24 07:30AM	Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars (Business Wire)
Apr-24-24 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results (Business Wire)
07:30AM	Loading…
07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease (Business Wire)
Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-07-24 09:00AM	Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo (Business Wire)
Apr-04-24 01:27AM	Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ... (GuruFocus.com)
Apr-01-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Mar-25-24 08:00AM	Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data (Business Wire)
Mar-11-24 06:53PM	The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024 (InvestorPlace) -12.11%
Mar-08-24 11:29PM	Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares (GuruFocus.com)
07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy (Business Wire)
Mar-04-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences (Business Wire)
10:42AM	Loading…
Feb-07-24 10:42AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:02AM	Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-06-24 04:32PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:32PM	Arrowhead Pharmaceuticals Inc Reports Fiscal Q1 2024 Results with Strategic Focus on ... (GuruFocus.com)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results (Business Wire)
Jan-22-24 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results (Business Wire)
Jan-18-24 05:37AM	Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential (TipRanks)
Jan-09-24 03:02AM	Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 16,104 Shares (GuruFocus.com)
Jan-06-24 01:01PM	Arrowhead Pharmaceuticals Inc Insider Sells Shares (GuruFocus.com)
Jan-05-24 05:00PM	Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million (Business Wire)
11:02AM	Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 9,952 Shares (GuruFocus.com)
Jan-03-24 07:00AM	Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock (Business Wire)
Dec-29-23 04:01PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Dec-24-23 09:01AM	Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 Shares (GuruFocus.com)
Dec-21-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease (Business Wire)
07:30AM	Loading…
Dec-20-23 07:30AM	Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) -7.23%
Dec-01-23 09:32AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.29%
Nov-30-23 12:22PM	Q4 2023 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -26.85%
Nov-29-23 04:51PM	Arrowhead Pharmaceuticals Inc Reports Fiscal 2023 Year-End Results (GuruFocus.com)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results (Business Wire)
Nov-28-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy (Business Wire)
Nov-22-23 09:46PM	Insider Sell Alert: Chief Medical Officer Martin San Sells 19,700 Shares of Arrowhead ... (GuruFocus.com)
Nov-21-23 04:01PM	Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-16-23 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results (Business Wire)
Nov-13-23 09:30AM	Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023 (Business Wire)
Nov-06-23 07:30AM	Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference (Business Wire)
Nov-02-23 07:30AM	Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023 (Business Wire)
Oct-31-23 08:30AM	UPDATE 1-GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy (Reuters) +5.90%
07:46AM	GSK signs $1 bln deal for exclusive license to J&J's hepatitis B therapy (Reuters)
Oct-28-23 05:02AM	Insider Sell: CEO Christopher Anzalone Sells 24,338 Shares of Arrowhead Pharmaceuticals Inc (GuruFocus.com)
Oct-03-23 04:01PM	Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences (Business Wire)
Sep-27-23 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Sep-21-23 05:01AM	Insider Sell: CEO Christopher Anzalone Sells 57,755 Shares of Arrowhead Pharmaceuticals Inc (GuruFocus.com)
Sep-11-23 07:30AM	Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023 (Business Wire)
Sep-09-23 03:59PM	10 Biotech Stocks with Biggest Upside (Insider Monkey)
Sep-07-23 07:34PM	Is Arrowhead Pharmaceuticals (ARWR) Too Good to Be True? A Comprehensive Analysis of a ... (GuruFocus.com)
Sep-01-23 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences (Business Wire)
Aug-13-23 08:32AM	Swelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 99% over 5 years (Simply Wall St.)
Aug-10-23 08:10AM	ARWR: Enrollment Complete in PALISADE Phase 3 Trial of ARO-APOC3 in FCS... (Zacks)
Aug-08-23 09:42AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript (Insider Monkey) -10.78%
09:13AM	Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Aug-07-23 04:16PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (AP Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results (Business Wire)
Jul-24-23 04:00PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results (Business Wire)
Jul-17-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy (Business Wire)
Jul-06-23 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-30-23 06:52AM	Daily Vickers Top Buyers & Sellers for 06/30/2023 (Argus Research)
Jun-27-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1 (Business Wire)
Jun-24-23 08:15AM	Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease (Business Wire)
Jun-21-23 08:00PM	ARWR: What does Argus have to say about ARWR? (Argus Research)
Jun-14-23 06:34PM	Goldman Sachs Lifts S&P 500 Price Target; Here Are 2 High-Upside Stocks to Play the Bounce (TipRanks)
Jun-06-23 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences (Business Wire)
Jun-01-23 04:07PM	Arrowhead CEO Christopher Anzalone Addresses This 'Really Important Event' In Lung Disease (Investor's Business Daily)
07:30AM	Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics (Business Wire)
07:07AM	After a year of 4.1% returns, Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) share price drop last week may have less of an impact on institutional investors (Simply Wall St.)
May-23-23 07:30AM	Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH (Business Wire)
May-16-23 07:30AM	Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome (Business Wire) -5.64%
May-15-23 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming Conferences (Business Wire)
May-11-23 09:27AM	ARWR: Interim Data for Phase 1/2 Trial of ARO-RAGE Shows Potential for Pulmonary TRiM Platform (Zacks Small Cap Research)
May-10-23 06:25AM	Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth? (Insider Monkey)
May-04-23 06:24AM	Arrowhead Pharmaceuticals Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-02-23 04:17PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (AP Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results (Business Wire)
Apr-26-23 08:00PM	ARWR: Rating decreased to a SELL (Argus Research) +5.78%
07:06AM	Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates (Zacks)
Apr-25-23 01:19PM	Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars (Benzinga) +11.86%
11:20AM	Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday (Motley Fool)
07:30AM	Arrowhead Pharmaceuticals Proprietary Pulmonary TRiM Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect (Business Wire)
Apr-18-23 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results (Business Wire)
Apr-17-23 08:17AM	Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up (Simply Wall St.)
Apr-16-23 05:21AM	Is Arrowhead Pharmaceuticals a Buy Now? (Motley Fool)
Apr-12-23 07:30AM	Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics (Business Wire) +8.88%
Apr-04-23 04:30PM	2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street (Motley Fool)
07:30AM	First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead (Business Wire)
Apr-03-23 07:30AM	Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK (Business Wire)
Mar-31-23 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Mar-20-23 07:30AM	Arrowhead Receives FDA Fast Track Designation for ARO-APOC3 (Business Wire)
Mar-06-23 05:28AM	Investing in Arrowhead Pharmaceuticals (NASDAQ:ARWR) five years ago would have delivered you a 329% gain (Simply Wall St.)
Mar-03-23 07:30AM	Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference (Business Wire)
Feb-28-23 07:30AM	Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases (Business Wire)
Feb-26-23 08:04AM	12 High Growth Healthcare Stocks to Buy (Insider Monkey)
Feb-15-23 11:29AM	JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals (Benzinga)
07:30AM	Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results (Business Wire)
Feb-08-23 02:13PM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2023 Earnings Call Transcript (Insider Monkey)

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hamilton James C	Chief Discovery/Trans Medicine	Apr 01 '24	Sale	28.03	6,000	168,180	204,851	Apr 03 06:05 PM
Lu Hongbo	Director	Mar 20 '24	Buy	27.50	1,000	27,500	33,680	Mar 20 07:06 PM
Lu Hongbo	Director	Mar 19 '24	Buy	28.00	1,000	28,000	32,680	Mar 20 07:06 PM
Lu Hongbo	Director	Mar 18 '24	Buy	27.49	1,000	27,490	31,680	Mar 20 07:06 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Mar 06 '24	Sale	35.19	40,000	1,407,600	400,600	Mar 08 05:54 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Option Exercise	14.54	57,499	836,035	3,772,547	Feb 02 05:25 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Sale	32.35	57,499	1,860,019	3,715,048	Feb 02 05:25 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 12 '24	Sale	36.89	7,940	292,904	210,851	Jan 17 06:32 PM
Vakiener Victoria	Director	Jan 11 '24	Sale	38.10	4,720	179,813	32,001	Jan 16 06:06 PM
Waddill William D.	Director	Jan 11 '24	Sale	38.07	3,934	149,759	47,870	Jan 16 06:06 PM
Ferrari Mauro	Director	Jan 11 '24	Sale	38.06	3,147	119,787	60,778	Jan 16 06:06 PM
GIVEN DOUGLAS B	Director	Jan 11 '24	Sale	38.06	2,911	110,788	129,711	Jan 16 06:06 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 05 '24	Sale	35.18	32,143	1,130,748	218,791	Jan 05 08:02 PM
O'Brien Patrick	COO and General Counsel	Jan 05 '24	Sale	35.27	22,841	805,716	464,385	Jan 05 07:58 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 05 '24	Sale	35.27	16,104	567,910	440,600	Jan 08 05:16 PM
San Martin Javier	Chief Medical Officer	Jan 05 '24	Sale	35.26	8,303	292,804	198,497	Jan 08 05:16 PM
Oliver Tracie	Chief Commercial Officer	Jan 05 '24	Sale	33.89	74	2,508	136,501	Jan 08 05:17 PM
O'Brien Patrick	COO and General Counsel	Jan 04 '24	Sale	32.63	1,600	52,208	402,226	Jan 05 07:58 PM
O'Brien Patrick	COO and General Counsel	Jan 03 '24	Sale	32.28	8,749	282,439	403,826	Jan 05 07:58 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 03 '24	Sale	32.19	6,300	202,781	175,934	Jan 05 08:02 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '24	Sale	31.01	9,952	308,637	3,715,048	Jan 04 05:25 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 20 '23	Sale	28.54	12,000	342,480	3,725,000	Dec 22 05:04 PM
San Martin Javier	Chief Medical Officer	Nov 20 '23	Sale	28.80	19,700	567,315	131,800	Nov 22 02:31 PM
Anzalone Christopher Richard	Chief Executive Officer	Oct 25 '23	Sale	24.21	24,338	589,223	3,737,000	Oct 27 06:23 PM
Vakiener Victoria	Director	Sep 28 '23	Sale	26.33	1,550	40,812	21,734	Oct 02 05:51 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 18 '23	Option Exercise	4.75	57,755	274,336	3,819,093	Sep 20 06:10 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 18 '23	Sale	28.12	57,755	1,624,223	3,761,338	Sep 20 06:10 PM
Oliver Tracie	Chief Commercial Officer	Jul 03 '23	Sale	35.31	8,925	315,142	61,575	Jul 06 06:04 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jun 30 '23	Sale	35.53	3,000	106,590	188,484	Jul 05 06:15 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jun 27 '23	Sale	36.20	15,000	543,000	381,704	Jun 29 06:41 PM

Open in Screener

TERN

Terns Pharmaceuticals Inc

May 03 • 04:00PM ET

5.44

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

TERN Terns Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM VXF IBB IWO VTWO VHT IWN IWC DFAC

Index	RUT	P/E	-	EPS (ttm)	-1.27	Insider Own	36.39%	Shs Outstand	64.58M	Perf Week	10.79%
Market Cap	351.80M	Forward P/E	-	EPS next Y	-1.40	Insider Trans	-1.76%	Shs Float	41.14M	Perf Month	-0.91%
Income	-90.21M	PEG	-	EPS next Q	-0.35	Inst Own	76.18%	Short Float	10.69%	Perf Quarter	7.72%
Sales	0.00M	P/S	-	EPS this Y	-9.27%	Inst Trans	32.54%	Short Ratio	4.78	Perf Half Y	3.62%
Book/sh	3.95	P/B	1.38	EPS next Y	-0.78%	ROA	-32.48%	Short Interest	4.40M	Perf Year	-57.83%
Cash/sh	4.07	P/C	1.34	EPS next 5Y	-	ROE	-33.89%	52W Range	3.26 - 13.51	Perf YTD	-16.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.40%	ROI	-35.33%	52W High	-59.73%	Beta	-0.49
Dividend TTM	-	Quick Ratio	22.39	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	66.87%	ATR (14)	0.40
Dividend Ex-Date	-	Current Ratio	22.39	EPS Y/Y TTM	30.50%	Oper. Margin	0.00%	RSI (14)	51.93	Volatility	6.96% 6.64%
Employees	66	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.50	Target Price	14.21
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-0.45%	Payout	-	Rel Volume	0.00	Prev Close	5.44
Sales Surprise	-	EPS Surprise	1.09%	Sales Q/Q	-	Earnings	Mar 14 AMC	Avg Volume	919.98K	Price	5.44
SMA20	8.96%	SMA50	-11.61%	SMA200	-6.49%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-22-23	Initiated	Mizuho	Buy	$16
Jun-07-23	Initiated	Jefferies	Buy	$18
May-31-23	Initiated	ROTH MKM	Buy	$23
May-08-23	Initiated	BMO Capital Markets	Outperform	$18
Feb-14-23	Initiated	JMP Securities	Mkt Outperform	$17
Feb-07-23	Initiated	UBS	Buy	$19
Sep-12-22	Initiated	H.C. Wainwright	Neutral	$6
Sep-14-21	Resumed	Goldman	Buy	$21
Mar-02-21	Initiated	JP Morgan	Overweight	$32
Mar-02-21	Initiated	Goldman	Buy	$29
Mar-02-21	Initiated	Cowen	Outperform

Show Previous Ratings

May-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Apr-29-24 04:05PM	Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation (GlobeNewswire)
Apr-10-24 04:05PM	Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer (GlobeNewswire) -5.23%
Mar-14-24 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates (GlobeNewswire) -5.23%
Mar-11-24 04:05PM	Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire) -8.38%
04:05PM	Loading…
Mar-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Feb-27-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences (GlobeNewswire) +5.69%
Feb-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.13%
08:05AM	Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer (GlobeNewswire)
Feb-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-04-24 04:05PM	Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.52%
Jan-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-29-23 04:05PM	Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-27-23 04:05PM	Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer (GlobeNewswire)
Nov-14-23 12:16PM	Terns Pharmaceuticals Inc (TERN) Reports Q3 2023 Financials and Corporate Progress (GuruFocus.com) +5.34%
08:05AM	Loading…
08:05AM	Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Nov-13-23 08:05AM	Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 08:05AM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire) -21.89%
Nov-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-02-23 04:05PM	Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity (GlobeNewswire) -8.00%
Oct-19-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.61%
Oct-16-23 08:05AM	Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire)
Oct-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-06-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-05-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-08-23 04:15PM	Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
04:05PM	Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH (GlobeNewswire)
Aug-03-23 06:00PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
05:05PM	Terns Pharmaceuticals Announces Leadership Transition (GlobeNewswire)
Jul-28-23 07:01PM	Deep Track Capital, LP Enters Position in Terns Pharmaceuticals Inc (GuruFocus.com)
04:05PM	Loading…
Jul-18-23 04:05PM	Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia (GlobeNewswire)
Jul-05-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jun-26-23 04:05PM	Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADAs 83rd Annual Scientific Session and Upcoming Events (GlobeNewswire) -12.16%
Jun-06-23 04:30PM	Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-02-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
May-28-23 09:45AM	Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth (Simply Wall St.)
May-25-23 05:05PM	Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting (GlobeNewswire)
May-24-23 04:05PM	Terns Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-22-23 04:05PM	Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Associations 83rd Annual Scientific Sessions (GlobeNewswire) +11.79%
May-15-23 08:05AM	Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire) -6.24%
May-09-23 04:05PM	Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference (GlobeNewswire)
May-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.61%
Apr-25-23 12:00PM	Terns Pharmaceuticals, Inc. (TERN) Is Up 15.12% in One Week: What You Should Know (Zacks) -5.29%
Mar-30-23 02:28PM	Why Shares of Terns Pharmaceuticals Soared This Week (Motley Fool)
Mar-27-23 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates (GlobeNewswire) +5.83%
08:05AM	Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology (GlobeNewswire)
Mar-08-23 05:26AM	Investing in Terns Pharmaceuticals (NASDAQ:TERN) a year ago would have delivered you a 211% gain (Simply Wall St.)
Mar-02-23 04:05PM	Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences (GlobeNewswire)
Feb-26-23 10:51AM	TipRanks Perfect 10 List: 3 Top-Rated Stocks That Tick All the Right Boxes (TipRanks)
Feb-08-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Terns Pharmaceuticals, Inc. (TERN) is a Great Choice (Zacks)
Feb-02-23 04:05PM	Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference (GlobeNewswire) +5.26%
Jan-12-23 04:05PM	Terns Pharmaceuticals to Present at B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire) +8.83%
Jan-05-23 04:05PM	Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-22 04:05PM	Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -7.20%
Dec-20-22 07:40PM	Terns Announces Pricing of $75 Million Public Offering (GlobeNewswire) -5.59%
08:05AM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-19-22 04:31PM	Terns Announces Proposed Public Offering (GlobeNewswire) +30.28%
Dec-01-22 04:05PM	Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit (GlobeNewswire) -10.30%
Nov-16-22 09:31AM	We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate (Simply Wall St.)
Nov-09-22 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) -8.10%
Nov-04-22 08:05AM	Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022 (GlobeNewswire)
Oct-26-22 04:05PM	Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022 (GlobeNewswire)
Oct-12-22 05:26AM	Zacks.com featured highlights include Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE (Zacks)
Oct-11-22 04:05PM	Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference (GlobeNewswire) +13.39%
Sep-29-22 06:03AM	The past year for Terns Pharmaceuticals (NASDAQ:TERN) investors has not been profitable (Simply Wall St.)
Sep-21-22 05:33AM	Zacks.com featured highlights include Terns Pharmaceuticals, Napco Security Technologies and AVEO (Zacks) -7.21%
Sep-07-22 04:05PM	Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-19-22 06:50AM	Terns Pharmaceuticals, Inc.'s (NASDAQ:TERN) market cap surged US$112m last week, individual investors who have a lot riding on the company were rewarded (Simply Wall St.)
Aug-12-22 08:00AM	Terns Announces $65 Million Oversubscribed Offering (GlobeNewswire) +25.31%
Aug-08-22 04:05PM	Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-27-22 04:05PM	Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors (GlobeNewswire)
Jul-22-22 12:00PM	All You Need to Know About Terns Pharmaceuticals, Inc. (TERN) Rating Upgrade to Buy (Zacks)
Jun-22-22 04:05PM	Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress 2022 (GlobeNewswire) +7.22%
Jun-09-22 06:31AM	We're Keeping An Eye On Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate (Simply Wall St.)
Jun-08-22 04:05PM	Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022 (GlobeNewswire)
Jun-01-22 04:05PM	Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer (GlobeNewswire)
May-16-22 04:05PM	Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
Apr-05-22 01:38PM	Investors in Terns Pharmaceuticals (NASDAQ:TERN) have unfortunately lost 86% over the last year (Simply Wall St.)
Apr-04-22 04:05PM	Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-22 04:05PM	Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201 (GlobeNewswire)
Mar-03-22 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-28-22 04:05PM	Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference (GlobeNewswire)
Feb-04-22 11:37AM	Terns Pharmaceuticals, Inc. (NASDAQ:TERN): Are Analysts Optimistic? (Simply Wall St.) -5.13%
Feb-02-22 05:38PM	Matthews International Capital Management Llc Buys Atlassian Corporation PLC, Pinduoduo Inc, ... (GuruFocus.com) -12.59%
Jan-06-22 07:05AM	Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer (GlobeNewswire)
Jan-03-22 04:05PM	Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference (GlobeNewswire) -5.23%
Nov-15-21 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Nov-12-21 07:05AM	Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021 (GlobeNewswire)
Nov-10-21 07:17AM	Terns' Potential NASH Candidate Shows Potent Liver Target Engagement (Benzinga)
Nov-09-21 04:05PM	Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR- agonist TERN-501 (GlobeNewswire) -5.49%
Nov-03-21 02:52PM	Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Oct-18-21 04:05PM	Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experience 2021 (GlobeNewswire)
Oct-05-21 04:05PM	Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference (GlobeNewswire)
Oct-04-21 08:38AM	Should I Avoid Terns Pharmaceuticals, Inc. (TERN)? (Insider Monkey)
Sep-28-21 04:05PM	Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors (GlobeNewswire)
Sep-15-21 06:07PM	Goldman Sachs Sees These 2 Stocks Surging Over 70% (TipRanks)
Sep-08-21 07:05AM	Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201 (GlobeNewswire) -6.67%
Sep-02-21 04:05PM	Terns Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-16-21 04:05PM	Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire) -11.01%
Aug-03-21 04:05PM	Terns Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vivo Opportunity, LLC	10% Owner	Apr 03 '24	Sale	6.20	138,066	856,009	268,573	Apr 03 08:47 PM
Vivo Opportunity, LLC	10% Owner	Apr 02 '24	Sale	6.65	101,480	674,842	272,722	Apr 03 08:47 PM
Vivo Opportunity, LLC	10% Owner	Apr 01 '24	Sale	6.99	181,117	1,266,008	275,772	Apr 03 08:47 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ARWR

Arrowhead Pharmaceuticals Inc.

TERN

Terns Pharmaceuticals Inc

Upgrade your FINVIZ experience